Selected research
Industry Research
Gonadotropin-releasing Hormone Agonist Drugs Industry Research Report 2026
Market perspective
The global Gonadotropin-releasing Hormone Agonist Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gonadotropin-releasing Hormone Agonist Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gonadotropin-releasing Hormone Agonist Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gonadotropin-releasing Hormone Agonist Drugs include Endo, Ferring, Ipsen, LIVZON, TerSera Therapeutics, AstraZeneca, AbbVie, Sanofi and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gonadotropin-releasing Hormone Agonist Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gonadotropin-releasing Hormone Agonist Drugs Market by Company
Endo
Ferring
Ipsen
LIVZON
TerSera Therapeutics
AstraZeneca
AbbVie
Sanofi
Takeda
Gonadotropin-releasing Hormone Agonist Drugs Segment by Type
Histrelin
Taltirelin
Leuprorelin
Goserelin
Other
Gonadotropin-releasing Hormone Agonist Drugs Segment by Application
Hospital
Pharmacy
Other
Gonadotropin-releasing Hormone Agonist Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gonadotropin-releasing Hormone Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gonadotropin-releasing Hormone Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gonadotropin-releasing Hormone Agonist Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gonadotropin-releasing Hormone Agonist Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gonadotropin-releasing Hormone Agonist Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gonadotropin-releasing Hormone Agonist Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Histrelin
- Taltirelin
- Leuprorelin
- Goserelin
- Other
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Endo
- Ferring
- Ipsen
- LIVZON
- TerSera Therapeutics
- AstraZeneca
- AbbVie
- Sanofi
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Market Size (2021-2032)
- 2.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales (2021-2032)
- 2.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Market Average Price (2021-2032)
- 2.3 Gonadotropin-releasing Hormone Agonist Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Histrelin
- 2.3.3 Taltirelin
- 2.3.4 Leuprorelin
- 2.3.5 Goserelin
- 2.3.6 Other
- 2.4 Gonadotropin-releasing Hormone Agonist Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Gonadotropin-releasing Hormone Agonist Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Gonadotropin-releasing Hormone Agonist Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gonadotropin-releasing Hormone Agonist Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gonadotropin-releasing Hormone Agonist Drugs, Product Type & Application
- 3.8 Global Manufacturers of Gonadotropin-releasing Hormone Agonist Drugs, Established Date
- 3.9 Global Gonadotropin-releasing Hormone Agonist Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Endo
- 4.1.1 Endo Company Information
- 4.1.2 Endo Business Overview
- 4.1.3 Endo Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Endo Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.1.5 Endo Recent Developments
- 4.2 Ferring
- 4.2.1 Ferring Company Information
- 4.2.2 Ferring Business Overview
- 4.2.3 Ferring Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ferring Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.2.5 Ferring Recent Developments
- 4.3 Ipsen
- 4.3.1 Ipsen Company Information
- 4.3.2 Ipsen Business Overview
- 4.3.3 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.3.5 Ipsen Recent Developments
- 4.4 LIVZON
- 4.4.1 LIVZON Company Information
- 4.4.2 LIVZON Business Overview
- 4.4.3 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.4.5 LIVZON Recent Developments
- 4.5 TerSera Therapeutics
- 4.5.1 TerSera Therapeutics Company Information
- 4.5.2 TerSera Therapeutics Business Overview
- 4.5.3 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.5.5 TerSera Therapeutics Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 AbbVie
- 4.7.1 AbbVie Company Information
- 4.7.2 AbbVie Business Overview
- 4.7.3 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.7.5 AbbVie Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.8.5 Sanofi Recent Developments
- 4.9 Takeda
- 4.9.1 Takeda Company Information
- 4.9.2 Takeda Business Overview
- 4.9.3 Takeda Gonadotropin-releasing Hormone Agonist Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Takeda Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
- 4.9.5 Takeda Recent Developments
5 Global Gonadotropin-releasing Hormone Agonist Drugs Market Scenario by Region
- 5.1 Global Gonadotropin-releasing Hormone Agonist Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021-2032
- 5.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021-2026
- 5.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2027-2032
- 5.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region: 2027-2032
- 5.4 North America Gonadotropin-releasing Hormone Agonist Drugs Market Facts & Figures by Country
- 5.4.1 North America Gonadotropin-releasing Hormone Agonist Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
- 5.4.3 North America Gonadotropin-releasing Hormone Agonist Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Gonadotropin-releasing Hormone Agonist Drugs Market Facts & Figures by Country
- 5.5.1 Europe Gonadotropin-releasing Hormone Agonist Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Gonadotropin-releasing Hormone Agonist Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gonadotropin-releasing Hormone Agonist Drugs Market Facts & Figures by Country
- 5.7.1 South America Gonadotropin-releasing Hormone Agonist Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
- 5.7.3 South America Gonadotropin-releasing Hormone Agonist Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021-2032)
- 6.1.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Gonadotropin-releasing Hormone Agonist Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021-2032)
- 7.1.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Gonadotropin-releasing Hormone Agonist Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gonadotropin-releasing Hormone Agonist Drugs Value Chain Analysis
- 8.1.1 Gonadotropin-releasing Hormone Agonist Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gonadotropin-releasing Hormone Agonist Drugs Production Mode & Process
- 8.2 Gonadotropin-releasing Hormone Agonist Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gonadotropin-releasing Hormone Agonist Drugs Distributors
- 8.2.3 Gonadotropin-releasing Hormone Agonist Drugs Customers
9 Global Gonadotropin-releasing Hormone Agonist Drugs Analyzing Market Dynamics
- 9.1 Gonadotropin-releasing Hormone Agonist Drugs Industry Trends
- 9.2 Gonadotropin-releasing Hormone Agonist Drugs Industry Drivers
- 9.3 Gonadotropin-releasing Hormone Agonist Drugs Industry Opportunities and Challenges
- 9.4 Gonadotropin-releasing Hormone Agonist Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst